1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
KUKJE PHARMA Co., Ltd.

KUKJE PHARMA Co., Ltd.

KKRX:002720
3,545.00
KRW
-60.00
(-1.66%)
238.26EPS
13.91P/E
70.25BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
6,028.89
6,122.47
5,787.59
5,847.79
6,119.12
5,302.96
5,484.16
6,135.62
5,642.65
5,964.52
6,675.99
7,695.13
8,624.41
8,649.9
Basic EPS, GAAP
106.36
-346.67
-292.38
37.46
54.2
107.98
-234.96
103.66
-73.47
167.62
-415
256
280
238.65
Free Cash Flow per Basic Share
-319.32
-122.54
-308.12
649.85
-164.92
482.43
-112.67
-305.83
359.85
246.29
124.73
46.49
96.65
108.61
Dividend per Share
- -
7.17
7.27
- -
7.83
8.13
25.42
- -
- -
- -
- -
- -
30.02
- -
Book Value per Share
3,002.21
2,666.79
3,306.8
3,482.29
3,474.36
3,454.83
3,005.63
3,476.9
3,383.53
3,656.47
4,194.43
4,397.39
4,616.7
4,695.84
Tangible Book Value per Share
2,949.42
2,626.82
3,270.18
3,411.12
3,331.1
3,360.61
2,922.88
3,403.29
3,317.74
3,600.91
4,149.04
4,354.66
4,551.19
4,633.11
Basic Weighted Avg Shares
20
20
20
21
20
20
20
21
21
21
20
20
20
21
Sales/Revenue/Turnover
120,461
122,426
117,637
120,684
123,310
107,681
111,122
130,395
119,746
126,583
135,373
156,463
175,496
181,267
Operating Margin (%)
0.87
-1.16
1.78
3.29
2.08
3.05
5.01
4.63
-1.4
4.17
-1.47
4.28
3.52
2.47
Depreciation Expense
4,077
3,780
3,357
2,887
2,642
2,741
3,251
3,626
4,419
4,488
4,204
3,203
3,226
3,369
Net Income, GAAP
2,125
-6,932
-5,943
773
1,092
2,193
-4,761
2,203
-1,559
3,557
-8,415
5,205
5,698
5,001
Effective Tax Rate (%)
- -
- -
- -
54.87
49.4
22.87
4,021.09
60.77
- -
25.34
- -
21.23
11.46
12.1
Profit Margin (%)
1.76
-5.66
-5.05
0.64
0.89
2.04
-4.28
1.69
-1.3
2.81
-6.22
3.33
3.25
2.76
Working Capital
39,226
16,354
34,521
10,506
8,960
6,360
1,884
-5,417
-6,319
680
-4,568
28,427
5,358
8,834
LT Debt
24,250
7,000
27,000
2,000
4,000
- -
2,256
3,792
1,620
1,196
476
27,342
294
1,051
Total Equity
58,329
50,853
68,459
67,519
67,778
68,698
60,954
70,499
68,588
74,079
84,950
89,548
97,702
99,370
Return on Invested Capital (%)
- -
- -
- -
1.72
1.3
2.58
-226.18
2.31
- -
3.88
- -
4.5
4.39
3.14
Return on Capital (%)
- -
- -
- -
1.23
1.57
2.9
-39.74
2.4
- -
4.17
- -
5.24
5.26
4.51
Return on Common Equity (%)
3.75
-12.71
-9.98
1.14
1.62
3.21
-7.35
3.35
-2.24
4.99
-10.58
5.97
6.09
5.19

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
30,110
30,193
30,337
LT Borrowings
- -
- -
- -
LT Finance Leases
294
727
1,051
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
21
21
21
Market Capitalization
90,987
101,250
70,251

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
67,377
64,721
72,514
Cash, Cash Equivalents & STI
10,724
9,377
15,722
Accounts Receivable, Net
23,978
25,986
25,007
Inventories
25,850
23,728
25,509
Total Current Liabilities
62,020
59,209
63,680
Payables & Accruals
- -
- -
- -
ST Debt
30,110
30,193
30,337
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.92%
6.9%
9.11%
Free Cash Flow
-102.75%
-51.04%
108.07%
Net Income, GAAP
-142.23%
-197.58%
9.46%
Sales/Revenue/Turnover
4.49%
6.44%
12.16%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
37,534
37,643
39,651
41,635
156,463
2025
41,504
45,023
45,633
43,336
175,496
2026
43,980
48,318
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
135
29
57
34.76
256
2025
91
131
94
-34.57
280
2026
101.53
79
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
30.02
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Tae-Hoon Nam
Full Time Employees
272
Sector
Health technology
Industry
Pharmaceuticals: major
Address
96-8, Yatap-ro Seongnam-si GY South Korea 06141
IPO Date
Dec 27, 1975
Website
kukjepharm.co.kr
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Kukje Pharma Co., Ltd. (002720.KS) manufactures, imports, exports, sells and distributes pharmaceutical products in South Korea. The company offers a broad portfolio of prescription and over-the-counter medications, including antibiotics such as cephalosporins, quinolones, tetracyclines, aminoglycosides and macrolides; ophthalmic agents encompassing RebaEye Ophthalmic Solution with rebamipide for dry eye syndrome, Cualone Eye Drops featuring sodium hyaluronate artificial tears in multiple concentrations, and DiquEye Eye Drops with diquafosol sodium; antifungal and antiviral agents; adrenal corticosteroids; central nervous system and osteoporotic agents; antihistamines; non-steroidal anti-inflammatory drugs and other analgesics; gastrointestinal and cardiovascular agents; antidiabetics; genitourinary and respiratory agents; vitamins; nutritional supplements; cosmetics; and health care products, alongside raw materials, intermediates and side chain products. Founded in 1959 and headquartered in Seongnam-si, Gyeonggi-do, South Korea, Kukje Pharma operates primarily in the domestic market with exports to regions including the U.A.E., China, Hong Kong, Malaysia, Qatar and Vietnam, serving hospitals, pharmacies and international distributors through approximately 244 employees. Recent developments include a co-promotion agreement signed with UK Chemipharm to jointly market and distribute five products from the UK Kit lineup, such as Trison Kit, aimed at enhancing clinical product awareness and patient benefits; plans to expand its Anseong Plant by adding a new production line for eye drops to boost manufacturing capacity; and ongoing efforts to grow its contract manufacturing organization business alongside new generic drug launches in antibiotics, respiratory and ophthalmic categories.